Paul Herendeen

Executive Vice President & Chief Financial Officer at Valeant Pharmaceuticals International Corp.

Paul Herendeen

Paul Herendeen

Executive Vice President & Chief Financial Officer at Valeant Pharmaceuticals International Corp.

Overview
Career Highlights

Bausch Health Cos., Inc.
Valeant Pharmaceuticals International Corp.
Zoetis, Inc.

RelSci Relationships

1837

Birthday

1956

Age

63

Relationships
RelSci Relationships are individuals Paul Herendeen likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chairman of the Board & Chief Executive Officer at Bausch Health Cos., Inc.

Relationship likelihood: Strong

Chief Financial Officer & Executive Vice President at Aton Pharma, Inc.

Relationship likelihood: Strong

Executive Vice President, General Counsel at Valeant Pharmaceuticals International Corp.

Relationship likelihood: Strong

Chief Accounting Officer, Senior Vice President & Controller at Valeant Pharmaceuticals International Corp.

Relationship likelihood: Strong

Former General Counsel at Warner Chilcott Ltd.

Relationship likelihood: Strong

President & Chief Executive Officer at Warner Chilcott Holdings Company III Ltd.

Relationship likelihood: Strong

Benefit Plan Administrator at Bausch + Lomb, Inc.

Relationship likelihood: Strong

President-Ortho Dermatologics at Bausch Health Cos., Inc.

Relationship likelihood: Strong

US President at Bausch + Lomb, Inc.

Relationship likelihood: Strong

President, Chief Executive Officer, Director at Obagi Medical Products, Inc.

Relationship likelihood: Strong

Paths to Paul Herendeen
Potential Connections via
Relationship Science
You
Paul Herendeen
Executive Vice President & Chief Financial Officer at Valeant Pharmaceuticals International Corp.
Education
Bachelor's in Business Administration

Boston College is one of the nation's best and most selective universities, with U.S. News & World Report ranking Boston College 31st among national universities, and Forbes ranking it 26th in its 2012 America's Best Colleges listing. Boston College confers more than 4,000 degrees annually in more than 50 fields of study through eight schools and colleges. Faculty members are committed to both teaching and research having earned nearly $60 million in research grants in the last year alone. The University has made a major commitment to academic excellence. As part of its Strategic Plan, Boston College is in the process of adding 100 new faculty positions, expanding faculty and graduate research, increasing student financial aid to more than $128 million annually, and widening opportunities in key undergraduate programs, such as international study, internships and student formation. Boston College has experienced tremendous growth in recent years, including a 75 percent increase in undergraduate applications over the past decade, to more than 34,000 for the 2,250 seats in its freshman class. During the same period, an increase in voluntary giving from alumni has helped to move the University's endowment to approximately $1.9 billion. Boston College students have also earned more than 200 prestigious academic scholarships over the past decade, including 2 Rhodes Scholarships, 4 Marshalls, 9 Goldwaters and 162 Fulbright grants.

Master of Business Administration in Finance

The University of Virginia Darden School of Business is one of the world's leading business schools, offering MBA, Ph.D. and Executive Education programs.The Darden School improves the world by developing and inspiring responsible leaders and by advancing knowledge.The unique Darden experience combines the case study method, the highest-ranked faculty whose research advances global managerial practice and business education, and a tight-knit learning environment to develop principled and complete leaders.

Career History
Executive Vice President & Chief Financial Officer
2016 - Current

Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment comprises of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The Salix Segment consists of sales in the U.S. of GI Products, The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Executive Vice President & Chief Financial Officer
Current

Valeant Pharmaceuticals International Corp. manufactures and distributes pharmaceutical products. The company was founded on November 29, 2011 and is headquartered in Bridgewater, NJ.

Executive Vice President & Chief Financial Officer
2014 - 2016

Zoetis is a global animal health company dedicated to supporting customers and their businesses in ever better ways. Building on more than 65 years of experience, we deliver quality medicines, vaccines and diagnostic products, complemented by genetic tests, biodevices and a range of services. We are working every day to better understand and address the real-world challenges faced by those who raise and care for animals in ways they find truly relevant.

Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
N/A
2007

Boston College is one of the nation's best and most selective universities, with U.S. News & World Report ranking Boston College 31st among national universities, and Forbes ranking it 26th in its 2012 America's Best Colleges listing. Boston College confers more than 4,000 degrees annually in more than 50 fields of study through eight schools and colleges. Faculty members are committed to both teaching and research having earned nearly $60 million in research grants in the last year alone. The University has made a major commitment to academic excellence. As part of its Strategic Plan, Boston College is in the process of adding 100 new faculty positions, expanding faculty and graduate research, increasing student financial aid to more than $128 million annually, and widening opportunities in key undergraduate programs, such as international study, internships and student formation. Boston College has experienced tremendous growth in recent years, including a 75 percent increase in undergraduate applications over the past decade, to more than 34,000 for the 2,250 seats in its freshman class. During the same period, an increase in voluntary giving from alumni has helped to move the University's endowment to approximately $1.9 billion. Boston College students have also earned more than 200 prestigious academic scholarships over the past decade, including 2 Rhodes Scholarships, 4 Marshalls, 9 Goldwaters and 162 Fulbright grants.

$1,000 - $2,499
2005
Political Donations
$200
2015

Founder at Young Guns Program

$250
2014

Founder at Young Guns Program

$250
2013

Founder at Young Guns Program

Transactions
Details Hidden

Warner Chilcott Plc issued Ordinary Shares

Details Hidden

Warner Chilcott Plc issued Ordinary Shares

Investments
Details Hidden

MedPointe, Inc. develops, markets, and sells therapeutics. The company's products include respiratory, allergy, central nervous system, cough/cold, and pediatric products. The company was founded by James S. Burns and Anthony H. Wild in 2001 and is headquartered in Somerset, NJ.

Public Holdings
Restricted data only for RelSci Professional users.
Events
Speaker
New York City, NY
2013 UBS Global Healthcare Conference

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Paul Herendeen. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Paul Herendeen's profile does not indicate a business or promotional relationship of any kind between RelSci and Paul Herendeen.